Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma

Phase

N/A

Condition

Liver Disease

Hepatic Fibrosis

Liver Disorders

Treatment

N/A

Clinical Study ID

NCT00769535

KMUH-IRB-930047

All Genders
Accepts Healthy Volunteers

Study Summary

Polymorphisms of HSP70 and tumor necrosis factor-alpha promoter in patients with hepatocellular carcinoma, chronic liver disease and healthy controls will be measured by PCR-RFLP or direct sequencing. The clinical relevance of patients will be compared in those with polymorphism and those without.

Eligibility Criteria

Inclusion

Inclusion Criteria:

History proven HCC patients

Exclusion

Exclusion Criteria:

No-definite diagnosed patients

Study Design

January 01, 2006

June 30, 2008

Study Description

Heat shock protein 70 (HSP 70) may be involved in various aspects of immune system including infection, autoimmunity, and tumor immunity. The relationship between HSP70 expression, disease activity and cancer prognosis varied according to type of cancer. The overexpression of HSP70 by tumor cells contributes to tumor behavior. HSP70 is present in normal and abnormal hepatocytes, and was reported to be over-expressed in both hepatoma cell lines and human hepatocellular carcinoma (HCC) tissue. Recent study indicated that HSP70 is a molecular marker during early hepatocarcinogenesis. It is also involved in anti-tumor immunity in HCC.We also investigate the polymorphism of tumor necrosis factor-alpha promoter, and correlated to clinical relevance.

Connect with a study center

Kaohsiung Medical University
Kaohsiung, 807
Taiwan
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.